MS HB1527

Prohibits health benefit plans, pharmacy benefit managers, and private review agents from denying coverage of antiretroviral drugs for HIV or AIDS treatment and prevention as "not medically necessary"

Bars use of prior authorization requirements, step therapy, or other protocols that could restrict or delay dispensing of antiretroviral drugs, including long-acting injectable FDA-approved medications

Requires health benefit plans to include at least one long-acting injectable antiretroviral medication in their formulary, with or without prior authorization requirement

Applies to all health benefit plans including private insurance, preferred provider organizations, health maintenance organizations, Medicaid fee-for-service, and Medicaid managed care programs

Takes effect July 1, 2024